Literature DB >> 11911281

Interferon-gamma inhibits growth and migration of A172 human glioblastoma cells.

M M Knüpfer1, H Knüpfer, V Jendrossek, S Van Gool, J E Wolff, E Keller.   

Abstract

Malignant gliomas are highly proliferative and invasive tumors with poor prognosis. We investigated the influence of Interferon-gamma (IFN-gamma) on the human malignant glioma cell line A172, measuring cell viability (MTT-test), proliferation (3H-thymidine-uptake), cell death (FACS) adhesion to hyaluronic acid (HA, adhesion-assay) and migration (Boyden-chamber). IFN-gamma significantly decreased cell viability and proliferation. Measured by FACS, an up-regulation of CD95 expression has been shown in combination with an increased rate of cell death, first seen after 96 hours IFN-gamma treatment. Adhesion to HA was decreased after pre-treatment with IFN-gamma. This was not mediated by down-regulation of the main HA-receptor CD44, since IFN-gamma did not change CD44 expression. IFN-gamma-treated cells showed a significantly diminished migration rate through a native or HA-coated 8-microm polycarbonate membrane. To summarise, IFN-gamma influences both the main characteristics of malignancy: it decreases cell proliferation and induces cell death, further it diminishes migration of A172 human glioblastoma cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11911281

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  8 in total

Review 1.  Big Potassium (BK) ion channels in biology, disease and possible targets for cancer immunotherapy.

Authors:  Lisheng Ge; Neil T Hoa; Zechariah Wilson; Gabriel Arismendi-Morillo; Xiao-Tang Kong; Rajeev B Tajhya; Christine Beeton; Martin R Jadus
Journal:  Int Immunopharmacol       Date:  2014-07-12       Impact factor: 4.932

2.  Maintenance treatment with interferon-gamma and low-dose cyclophosphamide for pediatric high-grade glioma.

Authors:  Johannes E A Wolff; Sabine Wagner; Christiane Reinert; Astrid Gnekow; R-D Kortmann; Joachim Kühl; Stefaan W Van Gool
Journal:  J Neurooncol       Date:  2006-04-28       Impact factor: 4.130

Review 3.  Cytokine networks in glioma.

Authors:  Kenichiro Iwami; Atsushi Natsume; Toshihiko Wakabayashi
Journal:  Neurosurg Rev       Date:  2011-06-09       Impact factor: 3.042

4.  Small cell lung cancer cells express the late stage gBK tumor antigen: a possible immunotarget for the terminal disease.

Authors:  Neil T Hoa; Lisheng Ge; Rajeev B Tajhya; Christine Beeton; Andrew N Cornforth; Amir Abolhoda; Nils Lambrecht; Maria DaCosta-Iyer; Yi Ouyang; Anthony P Mai; Erin Hong; Judy Shon; Michelle J Hickey; Kate L Erickson; Carol A Kruse; Martin R Jadus
Journal:  Am J Transl Res       Date:  2014-05-15       Impact factor: 4.060

5.  Persistent IL-10 production is required for glioma growth suppressive activity by Th1-directed effector cells after stimulation with tumor lysate-loaded dendritic cells.

Authors:  Steven De Vleeschouwer; Isabel Spencer Lopes; Jan L Ceuppens; Stefaan W Van Gool
Journal:  J Neurooncol       Date:  2007-03-15       Impact factor: 4.130

6.  An Eighteen Serum Cytokine Signature for Discriminating Glioma from Normal Healthy Individuals.

Authors:  Mamatha B Nijaguna; Vikas Patil; Alangar S Hegde; Bangalore A Chandramouli; Arimappamagan Arivazhagan; Vani Santosh; Kumaravel Somasundaram
Journal:  PLoS One       Date:  2015-09-21       Impact factor: 3.240

7.  Interferon γ suppresses dentin sialophosphoprotein in oral squamous cell carcinoma cells resulting in antitumor effects, via modulation of the endoplasmic reticulum response.

Authors:  Ioannis Gkouveris; Nikolaos G Nikitakis; Jaya Aseervatham; Kalu U E Ogbureke
Journal:  Int J Oncol       Date:  2018-10-10       Impact factor: 5.650

Review 8.  The scrambled story between hyaluronan and glioblastoma.

Authors:  Matías Arturo Pibuel; Daniela Poodts; Mariángeles Díaz; Silvia Elvira Hajos; Silvina Laura Lompardía
Journal:  J Biol Chem       Date:  2021-03-17       Impact factor: 5.157

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.